Tyra Biosciences(US:TYRA) Prnewswire·2026-02-23 22:30Core Insights - Tyra Biosciences, Inc. announced the acceptance of two abstracts for presentation at the 2026 ASCO Genitourinary Cancers Symposium, highlighting its focus on FGFR biology and precision medicine development [1] Group 1: Presentation Details - The first presentation is titled "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial," scheduled for February 27, 2026, from 11:30 AM to 12:45 PM PST [1] - The second presentation is a phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302), also on February 27, 2026, from 11:30 AM to 12:45 PM PST [1] Group 2: Company Overview - Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting FGFR biology, with a proprietary platform called SNÃ…P for rapid drug design [1] - The company has a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions, including oral dabogratinib, a potential first-in-class selective FGFR3 inhibitor [1] - Current planned clinical development includes three Phase 2 studies: SURF303 for low-grade upper tract urothelial carcinoma, SURF302 for intermediate risk non-muscle invasive bladder cancer, and BEACH301 for pediatric achondroplasia [1]